ClinicalTrials.gg
CompletedNCT06180980Updated Mar 7, 2025Results posted

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

A Phase 1 interventional study of Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jan 2021, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53 days (screening through follow-up call).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive at Screening
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 15-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening.
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Have previously received pirtobrutinib (LOXO-305) in any other study investigating pirtobrutinib (LOXO-305), within 30 days prior to Day 1
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    200 mg Pirtobrutinib: Treatment AB

    Participants received a single oral dose of 200 milligrams (mg) of pirtobrutinib administered in the morning on Day 1, under fasted conditions (Treatment A) followed by 200 mg pirtobrutinib administered orally in the morning on Day 8, under fed condition (Treatment B). A washout period of 7 days was maintained between Treatments A and B.

    Drug: Pirtobrutinib

  • Experimental
    200 mg Pirtobrutinib: Treatment BA

    Participants received a single oral dose of 200 mg pirtobrutinib administered in the morning on Day 1, under fed conditions (Treatment B) followed by 200 mg of pirtobrutinib administered orally in the morning on Day 8, under fasted conditions (Treatment A). A washout period of 7 days was maintained between Treatments A and B.

    Drug: Pirtobrutinib

Interventions

  • Administered orally.

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

    PK: AUC0-24 of pirtobrutinib was reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 1 and 8

  2. PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  3. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib

    PK: AUC0-inf of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  4. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

    PK: %AUCextrap of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  5. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

    PK: CL/F of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  6. PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib

    PK: t½ of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  7. PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  8. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  9. PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Pirtobrutinib

    PK: Lambda Z of pirtobrutinib was reported.

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

  10. PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib

    PK: Vz/F of pirtobrutinib was reported

    Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8

07

Results

Posted Mar 7, 2025

Participant flow

Participant flow — Overall Study
Milestone200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BA
Started1010
Received at least 1 dose of study drug1010
Completed1010
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib

PK: AUC0-24 of pirtobrutinib was reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · hour nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
hour nanogram per milliliter (h*ng/mL)200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib51700 ± 18.745500 ± 42.0
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
h*ng/mL200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib83900 ± 25.177800 ± 48.9
PrimaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib

PK: AUC0-inf of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib
h*ng/mL200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib85100 ± 25.079000 ± 48.3
PrimaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

PK: %AUCextrap of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · percentage of AUCextrap
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
percentage of AUCextrap200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib1.21 ± 43.71.25 ± 65.1
PrimaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

PK: CL/F of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
liter per hour (L/h)200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib2.35 ± 25.02.53 ± 48.3
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib

PK: t½ of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · hour
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib
hour200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib18.4 ± 22.219.2 ± 25.4
PrimaryPK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

PK: Cmax of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
nanogram per milliliter (ng/mL)200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib4200 ± 18.63250 ± 35.9
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Median · hour
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hour200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib3.00 (1.50 to 4.05)4.00 (2.50 to 8.00)
PrimaryPK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Pirtobrutinib

PK: Lambda Z of pirtobrutinib was reported.

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Pirtobrutinib
1/hour (1/h)200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
Subject 10.01990.0155
Subject 20.03550.0363
Subject 30.03080.0303
Subject 40.04570.0436
Subject 50.04730.0352
Subject 60.03330.0307
Subject 70.03940.0381
Subject 80.04270.0459
Subject 90.04040.0395
Subject 100.03150.0365
Subject 110.05540.0513
Subject 120.03020.0344
Subject 130.03310.0265
Subject 140.03620.0383
Subject 150.03820.0396
Subject 160.04660.0381
Subject 170.03920.0440
Subject 180.04320.0418
Subject 190.04080.0397
Subject 200.04080.0360
PrimaryPK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib

PK: Vz/F of pirtobrutinib was reported

Time frame:
Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
Reported as:
Geometric mean · liter
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib
liter200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib62.5 ± 21.270.1 ± 43.4

Adverse events

Collected over Baseline to end of follow-up (up to 24 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Pirtobrutinib (Fasted)0/20 (0%)0/20 (0%)2/20 (10%)
200 mg Pirtobrutinib (Fed)0/20 (0%)0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
Event200 mg Pirtobrutinib (Fasted)200 mg Pirtobrutinib (Fed)
DizzinessNervous system disorders1/200/20
DysgeusiaNervous system disorders1/200/20
HeadacheNervous system disorders0/201/20
DiarrhoeaGastrointestinal disorders0/201/20
Dry mouthGastrointestinal disorders0/201/20
PetechiaeSkin and subcutaneous tissue disorders1/200/20

Baseline characteristics

All participants who received at least 1 dose of Pirtobrutinib.

Age, Continuous
Age, Continuous(years)200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BATotal
Mean35.9 ± 10.1035.9 ± 11.1035.9 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BATotal
Female224
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BATotal
Hispanic or Latino6713
Not Hispanic or Latino437
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BATotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American325
White6814
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)200 mg Pirtobrutinib: Treatment AB200 mg Pirtobrutinib: Treatment BATotal
United States101020
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2021, 2 months.

Results were first posted in Mar 2025, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Jan 4, 2021
Primary completionActual
Mar 8, 2021
CompletionActual
Mar 8, 2021
Results first posted
Mar 7, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06180980
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Jan 4, 2021
Primary completion
Mar 8, 2021
Completion
Mar 8, 2021
Results posted
Mar 7, 2025
Last update
Mar 7, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion